North America’s medical devices industry saw a drop of 2.70% in deal activity during March 2022, when compared with the last 12-month average, led by Fresenius Kabi’s $240m acquisition of Ivenix, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 108 medical devices industry deals worth $1.9bn were announced for the region in March 2022, against the 12-month average of 111 deals.
Of all the deal types, venture financing saw most activity in March 2022 with 89 transactions, representing an 82.4% share for the region.
In second place was M&A with 11 deals, followed by private equity deals with eight transactions, respectively capturing a 10.2% and 7.4% share of the overall deal activity for the month.
In terms of value of deals, venture financing was the leading category in North America’s medical devices industry with $1.57bn, while M&A and private equity deals totalled $240m and $62m, respectively.
North America medical devices industry deals in March 2022: Top deals
The top five medical devices deals accounted for 39.8% of the overall value during March 2022.
The combined value of the top five medical devices deals stood at $745m, against the overall value of $1.87bn recorded for the month.
The top five medical devices industry deals of March 2022 tracked by GlobalData were:
1) Fresenius Kabi $240m acquisition deal with Ivenix
2) The $200m venture financing of DNAnexus by Blackstone Growth,Foresite Capital Management,GV Management Co,Innovatus Capital Partners,Northpond Ventures and Perceptive Advisors
3) Adams Street Partners,Baillie Gifford,Civilization Ventures,Fifty Years Fund,Hummingbird Ventures,Libertus Capital,NeoTribe Ventures,Norwest Venture Partners,Pacific 8 Ventures and Time BioVentures $125m venture financing deal with BillionToOne
4) The $100m venture financing of Visby Medical by Artiman Ventures,Blue Water Life Science Advisors,Cedars-Sinai Medical Center,Healthcare of Ontario Pension Plan,John Doerr,ND Capital,Nissim Capital,Ping An Voyager Partners and Pitango Venture Capital
5) Catalio Capital Management,First Albany Capital,Good Ventures,Illumina Ventures,Northpond Ventures and Novalis LifeSciences $80m venture financing deal with Sherlock Biosciences
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.